Skip to main content

Table 2 Frequency of diagnoses of blood–CSF barrier (B–CSF–B) dysfunction in the study population by sex, age and specific disease status

From: Increased age and male sex are independently associated with higher frequency of blood–cerebrospinal fluid barrier dysfunction using the albumin quotient

 FemaleMalep
All: n (%)718 (59.4)491 (40.6) 
Altered B-CSF-B: n (%)150 (20.1)216 (44.0)< 0.0001
 Age 16–40 years: n (%)37 (11.8)66 (40.8)< 0.0001
 Age 41–60 years: n (%)60 (23.4)78 (44.3)< 0.0001
 Age > 60 years: n (%)53 (33.3)72 (47.1)0.0134
MS: n (%)204 (68.7)93 (31.3) 
 Altered B-CSF-B: n (%)15 (7.35)23 (24.7)< 0.0001
OIND: n (%)132 (47.0)149 (53.0) 
 Altered B-CSF-B: n (%)60 (45.5)89 (59.7)0.0167
NIND: n (%)146 (49.2)151 (50.8) 
 Altered B-CSF-B: n (%)23 (15.8)50 (33.1)0.0005
UNK: n (%)236 (70.7)98 (29.3) 
 Altered B–CSF–B: n (%)52 (22.0)54 (55.1)< 0.0001
  1. B-CSF-B dysfunction was defined using the cerebrospinal fluid (CSF)/serum albumin quotient (QAlb) with the following upper reference limits: 6.5 for patients aged 16–40 years, 8.0 for patients aged 41–60 years and 9.0 for patients over 60 years. Chi square test was used for all comparisons
  2. ALL patient groups analysed as a whole, MS multiple sclerosis, NIND non-inflammatory neurological diseases, OIND other inflammatory neurological diseases, UNK unknown-neurological diagnosis